Candidiasis is one of the most widespread fungal infections globally. The efficacy of antifungal chemotherapy has become a public health concern due to the emergence and proliferation of drug-resistant Candida strains. It is within this context that we proposed to design, synthesize, and evaluate the antifungal activities of a new series of 2-styrylbenzimidazoles against a clinical strain of Candida glabrata. The objective of this work was to identify a potential antifungal lead compound to initiate its medicinal chemistry development. The 2-styrylbenzimidazoles used were conceptualized using medicinal chemistry techniques involving the hybridization of chemical entities with potential antifungal properties. The antifungal activities of the compounds were expressed as Minimum Inhibitory Concentrations (MICs), determined in vitro against a clinical strain of C. glabrata using the microplate dilution technique. All 10 evaluated compounds exhibited antifungal activity against the clinical strain of Candida glabrata. Furthermore, the derivative chlorinated at the 2-position of the benzene ring stood out for its particular efficacy against Candida, with an MIC of 12.26 μM. In conclusion, the derivative chlorinated at position 2 can be selected as the “hit molecule” from which further pharmacomodulations can be undertaken to obtain a drug candidate for the medicinal chemistry development of a new class of antifungals based on the 2-styrylbenzimidazole profile.
References
[1]
Valeix, N. (2019) Parasitology and Mycology. De Boeck Supérieur, 133 p.
[2]
Dodé, G., Jean, D. and Dante, B. (1984) Treatise on Medical Mycology. Payot, 482 p.
[3]
Whaley, S.G., Berkow, E.L., Rybak, J.M., Nishimoto, A.T., Barker, K.S. and Rogers, P.D. (2017) Azole Antifungal Resistance in Candida albicans and Emerging Non-Albicanscandida Species. FrontiersinMicrobiology, 7, Article 2173. https://doi.org/10.3389/fmicb.2016.02173
[4]
Krcmery, V. and Barnes, A.J. (2002) Non-Albicanscandida spp. Causing Fungaemia: Pathogenicity and Antifungal Resistance. Journal of Hospital Infection, 50, 243-260.
[5]
Mushi, M.F., Bader, O., Taverne-Ghadwal, L., Bii, C., Groß, U. and Mshana, S.E. (2017) Oral Candidiasis among African Human Immunodeficiency Virus-Infected Individuals: 10 Years of Systematic Review and Meta-Analysis from Sub-Saharan Africa. JournalofOralMicrobiology, 9, Article ID: 1317579. https://doi.org/10.1080/20002297.2017.1317579
[6]
Taverne-Ghadwal, L., Kuhns, M., Buhl, T., Schulze, M.H., Mbaitolum, W.J., Kersch, L., et al. (2022) Epidemiology and Prevalence of Oral Candidiasis in HIV Patients from Chad in the Post-Haart Era. FrontiersinMicrobiology, 13, Article 844069. https://doi.org/10.3389/fmicb.2022.844069
[7]
Aydemir, Ö., Demiray, T., Köroğlu, M., et al. (2017) Emerge of Non-Albicanscandida Species; Evaluation of Candida Species and Antifungal Susceptibilities According to Years. Biomedical Research, 28, 2820-2825.
[8]
Ben-Ami, R. and Kontoyiannis, D.P. (2021) Resistance to Antifungal Drugs. InfectiousDiseaseClinicsofNorthAmerica, 35, 279-311. https://doi.org/10.1016/j.idc.2021.03.003
[9]
Denning, D.W. (2022) Antifungal Drug Resistance: An Update. EuropeanJournalofHospitalPharmacy, 29, 109-112. https://doi.org/10.1136/ejhpharm-2020-002604
[10]
Meunier, B. (2011) Hybrid Molecules as a Strategy for Creating New Anti-Infective Agents. ComptesRendus Chimie, 14, 400-405.
[11]
Shaveta, S., Mishra, S. and Singh, P. (2016) Hybrid Molecules: The Privileged Scaffolds for Various Pharmaceuticals. European Journal of Medicinal Chemistry, 124, 500-536.
[12]
N’Guessan, D.J.P. (2018) Anticandidosic Activities of New Chalcones Vectorised by Benzimidazole against a Strain of Candida albicans Pharmacoresistance to Azoles. IOSR Journal of Pharmacy and Biological Sciences, 13, 11-16.
[13]
Songuigama, C., Ndu, J.P., Mahama, O. and Mamidou, K.W. (2019) Synthesis and Antifungal Activities of Benzimidazolyl-Arylpropenone Scaffolds as Promising Inhibitors of Azole-Resistant Candida Strains. European Journal of Biomedical and Pharmaceutical Sciences, 6, 19-25.
[14]
Tahlan, S., Kumar, S. and Narasimhan, B. (2019) Antimicrobial Potential of 1H-Benzo[d]Imidazole Scaffold: A Review. BMCChemistry, 13, Article No. 18. https://doi.org/10.1186/s13065-019-0521-y
[15]
Padalkar, V.S., Borse, B.N., Gupta, V.D., Phatangare, K.R., Patil, V.S., Umape, P.G., et al. (2016) Synthesis and Antimicrobial Activity of Novel 2-Substituted Benzimidazole, Benzoxazole and Benzothiazole Derivatives. Arabian Journal of Chemistry, 9, 1125-1130.
[16]
De Filippis, B., Ammazzalorso, A., Amoroso, R. and Giampietro, L. (2019) Stilbene Derivatives as New Perspective in Antifungal Medicinal Chemistry. Drug Development Research, 80, 285-293.
[17]
Kluska, M., Jabłońska, J. and Prukała, W. (2023) Analytics, Properties and Applications of Biologically Active Stilbene Derivatives. Molecules, 28, Article 4482. https://doi.org/10.3390/molecules28114482
[18]
Jain, D.K., Jain, N., Patel, V., Singhal, S. and Jain, S.K. (2015) Synthesis, Characterization and Antimicrobial Activity of Novel Substituted Cis-Stilbene Derivatives. WorldJournalofPharmacyandPharmaceuticalSciences, 4, 1473-1491.
[19]
Heck, R.F. and Nolley, J.P. (1972) Palladium-Catalyzed Vinylic Hydrogen Substitution Reactions with Aryl, Benzyl, and Styryl Halides. TheJournalofOrganicChemistry, 37, 2320-2322. https://doi.org/10.1021/jo00979a024
[20]
Woolley, D.W. (1944) Some Biological Effects Produced by Benzimidazole and Their Reversal by Purines. JournalofBiologicalChemistry, 152, 225-232. https://doi.org/10.1016/s0021-9258(18)72045-0
[21]
Ramaiah, K. and Ramanatham, J. (2000) Synthesis and Spectral Properties of 2-Styrylbenzimidazoles. Indian Journal of Chemistry, 39B, 904-914.
[22]
Jones, G. (2011) The Knoevenagel Condensation. In: OrganicReactions, John Wiley & Sons, Inc., 204-599. https://doi.org/10.1002/0471264180.or015.02
[23]
Kritikos, A., Neofytos, D., Khanna, N., et al. (2018) Accuracy of Sensititre YeastOne Echinocandins Epidemiological Cut-Off Values for Identification of FKS Mutant Candida albicans and Candida glabrata: A Ten Year National Survey of the Fungal Infection Network of Switzerland (FUNGINOS). Clinical Microbiology and Infection, 24, 1214.e1-1214.e4.
[24]
Coulibaly, S., N’guessan, J.P., Kone, M.W., et al. (2018) Anticandidosic Activities of New Chalcones Vectorised by Benzimidazole against a Strain of Candida albicans Pharmacoresistance to Azoles. IOSRJournalofPharmacyandBiologicalSciences, 13, 11-16.
[25]
Coulibaly, S., N’guessan, J.P., Kone, M.W., et al. (2014) Anti Candida L Activities of New Arylpropenones with Imidazopyridine Scaffold. AfriqueBiomédicale, 19, 43-48.
[26]
N’Guessan, J.P., Coulibaly, S., Molou, K.Y.G., et al. (2014) Anti-Candida albicans Activities of Some Benzothiazoles and Structural Analogues with Heteroaryl Scaffold. AfriqueBiomédicale, 19, 4-10.
[27]
Coulibaly, S., N’guessan, J.P., Ouattara, M., et al. (2019) Synthesis and Antifungal Activities of Benzimidazolyl-Arylpropenone Scaffolds as Promising Inhibitors of Azole-Resistant Candida Strains. EuropeanJournalofBiomedicalandPharmaceuticalSciences, 6, 19-25.
[28]
Coulibaly, S., Kone, A., N’guessan, J.P., et al. (2020) Design, Synthesis and Anticandidal Activities of Some Retrochalcones with Benzimidazole Nucleus. Journal of Pharmaceutical and Biological Sciences, 21, 5-11.
[29]
Ablé, N.C., N’guessan, D.U.J.-P., Yéhé, M.D., Coulibaly, S., et al. (2023) Determination of Analytical Parameters of Some 2-Arylvinyl Benzimidazole Derivatives by Liquid Chromatography Coupled with Tandem Mass Spectrometry (LC/MS/MS). International Journal of Pharmacy and Chemistry, 9, 67-77.
[30]
Bryskier, A. (1999) Antibacterial and Antifungal Agents. Ellipses, 1216 p.
[31]
AFECT (French Association of Teachers of Therapeutic Chemistry) (2000) Treatise on Therapeutic Chemistry, Volume 5: Main Antifungal and Antiparasitic Agents, Volume 2: Antiparasitics. Tec & Doc, 544 p.
[32]
Heeres, J., Meerpoel, L. and Lewi, P. (2010) Conazoles. Molecules, 15, 4129-4188. https://doi.org/10.3390/molecules15064129
[33]
Edwards, D.I. (1993) Nitroimidazole Drugs—Action and Resistance Mechanisms II. Mechanisms of Resistance. JournalofAntimicrobialChemotherapy, 31, 201-210. https://doi.org/10.1093/jac/31.2.201